ClinicalTrials.gov
public full text
Public Domain
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Graz Study on the Risk of Atrial Fibrillation#1151117
- AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke#858618
- Andexanet Alfa: Non-interventional Study in Stroke Units in Germany (DE)#834560
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events#845432
- Edoxaban Management in Diagnostic and Therapeutic Procedures#881366
Record · ID 877255
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive